Grace Therapeutics, Inc. (GRCE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has a cash flow conversion efficiency ratio of -0.034x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.22 Million) by net assets ($64.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GRCE equity financing ratio to measure how much of total assets are equity-financed.
Grace Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Grace Therapeutics, Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Grace Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grace Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avertronics
TWO:3597
|
0.003x |
|
Carmit
TA:CRMT
|
0.031x |
|
HPP Holdings Bhd
KLSE:0228
|
-0.006x |
|
MK Trend Co. Ltd.
KO:069640
|
-0.361x |
|
Vitreous Glass Inc
V:VCI
|
0.226x |
|
Mitie Group PLC
LSE:MTO
|
0.290x |
|
Cnova NV
PA:CNV
|
-0.063x |
|
Gadang Holdings Bhd
KLSE:9261
|
0.000x |
Annual Cash Flow Conversion Efficiency for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual cash flow conversion efficiency of Grace Therapeutics, Inc. from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see GRCE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $66.61 Million | $-14.90 Million | -0.224x | -12.02% |
| 2024-03-31 | $61.74 Million | $-12.33 Million | -0.200x | +14.70% |
| 2023-03-31 | $67.95 Million | $-15.91 Million | -0.234x | -47.11% |
| 2022-03-31 | $108.27 Million | $-17.23 Million | -0.159x | +38.13% |
| 2021-03-31 | $55.66 Million | $-14.32 Million | -0.257x | +85.43% |
| 2020-03-31 | $12.99 Million | $-22.95 Million | -1.766x | +21.30% |
| 2019-03-31 | $11.04 Million | $-24.79 Million | -2.244x | -47.43% |
| 2018-03-31 | $6.37 Million | $-9.69 Million | -1.522x | -530.30% |
| 2016-03-31 | $20.09 Million | $-4.85 Million | -0.242x | -11.49% |
| 2015-03-31 | $26.56 Million | $-5.75 Million | -0.217x | -5.95% |
| 2014-03-31 | $29.91 Million | $-6.12 Million | -0.204x | +22.00% |
| 2013-03-31 | $9.50 Million | $-2.49 Million | -0.262x | +32.45% |
| 2012-03-31 | $14.55 Million | $-5.65 Million | -0.388x | -18.23% |
| 2011-03-31 | $5.83 Million | $-1.91 Million | -0.328x | +30.67% |
| 2010-03-31 | $4.02 Million | $-1.90 Million | -0.473x | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more